GAP is proud to support the grand opening of #GAPNet El Faro Health and Therapeutics, the first private research site in Starr County, Texas. Starr County is a 97% Hispanic Community with the highest prevalence of Alzheimer’s disease in America. Legendary Starr County physician and Baylor College of Medicine Trustee, Dr. Antonio ‘Tony’ Falcon is […]
GAP President John Dwyer commends President Joe Biden on his commitment to fight Alzheimer’s, as well as calls on Congress to pass ARPA-H. Normally, presidential proclamations aren’t news. However, as the United States sinks deeper into a worsening Alzheimer’s public health crisis, President Joe Biden is making his priorities on the disease abundantly clear. Prior […]
Microsoft and Gates Ventures founder, Bill Gates, mentions GAP’s Bio-Hermes study to the World Dementia Council. We’ve all heard the statistics: Today, nearly 55 million people suffer from Alzheimer’s disease or related dementias. According to the WHO, dementia is the fastest growing burden on healthcare systems and the seventh leading cause of death worldwide. Its […]
Washington, DC (November 10, 2021) – The Global Alzheimer’s Platform Foundation® (GAP) welcomes Lynne Hughes, PhD, an international clinical trial research expert, as a Senior Advisor to the organization. Dr. Hughes will further expand GAP’s strength in developing global networks of clinical trial research institutions dedicated to accelerating the discovery of new assessments, treatments, and cures […]
Three GAP-Net Sites, The Cognitive and Research Center of New Jersey, Princeton Medical Institute, and Advanced Memory Research Institute of New Jersey are hosting a state wide FREE memory screening for individuals 50+. If you’re worried about the threat of dementia, there’s something you can do right now to reduce your risk. Get your memory […]
GAP-Net Site, Axiom Clinical Research of Florida, talks about the Bio-Hermes study and what people from traditionally underserved communities can do to get involved in research. We need an accessible means of diagnosing Alzheimer’s disease and research that demonstrates that new therapies and diagnostic tools work for all people. As a neurological researcher and an […]
GAP’s Bio-Hermes study was featured in BlackNews.com about our groundbreaking commitment to diversity. Washington, DC — Research sites in Florida, Illinois, Kansas, Texas, and New York are now recruiting participants for The Global Alzheimer’s Platform Foundation® (GAP)’s Bio-Hermes Study – a breakthrough Alzheimer’s clinical trial searching for cost-effective methods to assess the signs of the disease. It is […]
GAP-Net site, the University of Southern California, received over 90 grants totaling $92 million in 2020. USC’s bench is deep and its scope is wide when it comes to research on Alzheimer’s disease. In Paul Thompson’s lab, researchers query a vast trove of brain images and DNA from all over the world to glean insights that would be […]
GAP’s Tamiko MaGee-Rodgers, Associate Director for Recruitment and Strategic Initiatives, wrote an article in the Orlando Times about the Black community getting involved in Alzheimer’s disease clinical trials and the Bio-Hermes study at GAP-Net site, Charter Research. At the Global Alzheimer’s Platform Foundation (GAP), our focus is speeding the delivery of innovative therapies to people […]
GAP-Net site, Progressive Medical Research, was featured in the Daytona Times for the Bio-Hermes study and how to get a free brain scan. The effects of Alzheimer’s disease on Black families across the U.S. are devastating. If nothing is done to mitigate these effects, according to researchers at Florida International University and UsAgainstAlzheimer’s, by 2030 […]
GAP President John Dwyer and GAP-Net site, Charter Research, were featured in Being Patient talking about the Bio-Hermes study, our commitment to diversity, and the tests used in the study. Scientists have made strides in improving the precision of diagnosing Alzheimer’s, but available diagnostic tools that measure Alzheimer’s biomarkers remain inaccessible for many patients. So, […]
GAP President John Dwyer and GAP-Net site, Axiom Clinical Research, were featured in the Florida Courier about the Bio-Hermes study and the importance of Black and African American participation in Alzheimer’s trials. The effects of Alzheimer’s Disease on the Black families across the U.S. are devastating. If nothing is done to mitigate these effects, according […]
Contact: Peter Buonanno – peterbuonanno@rational360.com, 704-989-5501 WASHINGTON, D.C. (July 28, 2021) — Today, the Global Alzheimer’s Platform Foundation® (GAP) announced that Gates Ventures and the Alzheimer’s Disease Data Initiative (ADDI) will join the list of biopharma, technology, and nonprofit partners who are contributing to GAP’s breakthrough Alzheimer’s study, Bio-Hermes. Bio-Hermes is the first-ever platform study […]
GAP-Net site Washington Univeristy in St. Louis’ Dr. Joy Snider about the pros and cons about the approval of Aduhelm (Aducanumab). The recent FDA approval of a new Alzheimer’s drug has some researchers concerned — aside from its $56,000-a-year price tag. It’s the first Alzheimer’s drug to be approved since 2003. It’s called aducanumab and is marketed […]
Dr. Tamiko Magee-Rodgers joins the BNC to discuss the new Alzheimer`s drug, Aduhelm, and the role of minorities in clinical trials. Originally shown on BNC on July 9, 2021.
GAP Net site, Great Lakes Clinical Trials, spoke The Chicago Defender about GAP’s Bio-Hermes study and the importance of minority communities getting involved in Alzheimer’s clinical trials. Chicago’s Great Lakes Clinical Trials is now enrolling volunteers with and without memory concerns in the Global Alzheimer’s Platform Foundation’s Bio-Hermes Study. The study seeks to evaluate how […]
GAP-Net site Kerwin Medical Center in Dallas and GAP President John Dwyer were featured in D Magazine talking about how the Bio-Hermes study is making it easier for diverse populations to participate in its new Alzheimer’s trial. Dallas-based Kerwin Medical Center is emphasizing diversity as it enrolls patients in the Global Alzheimer’s Platform Foundation’s (GAP) […]
GAP-Net site Butler Hospital Memory and Aging Program administered the first infusion of Aduhelm to a patient who wasn’t involved in the clinical trial. A U.S. hospital on Wednesday gave the first infusion of an expensive, controversial new Alzheimer’s drug from Biogen Inc before Medicare had even said what it will pay for – and with […]
GAP President John Dwyer spoke to THE CALL about the health disparities in Alzheimer’s research and treatment between Black and African Americans compared to whites. If you have a family member or loved one going through Dementia you probably wish that you could turn back the clock about 15 years or to a time when […]
John Dwyer, GAP President, spoke about the impact Abucanumab will have on Alzheimer’s research and clinical trials going forward. The arrival of the first new Alzheimer’s drug in two decades should have been a moment of celebration. But so far, the healthcare industry is feeling concerned. The US Food and Drug Administration approved the new medication, […]
GAP President John Dwyer spoke to Scrip Informa Pharma Intelligence about Biogen’s aducanumab, and how clinical trials are more important than ever since it’s FDA approval. The requirement for Biogen, Inc. and Eisai Co., Ltd. to conduct a Phase IV clinical trialas a condition of Aduhelm’s accelerated approval raises the question of whether Alzheimer’s disease […]
The talk radio station in Dallas, Texas, WBAP, recently interviewed GAP President John Dwyer. After the FDA approval of Biogen’s Aducanumab, they included GAP’s statement commending the FDA. WASHINGTON (AP)- Government health officials on approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment […]
Patients and Doctors Deserve the Ability to Consider Whether Aducanumab Will Deliver the Best Medical Outcome and Quality of Life Washington, DC (June 7, 2021) – John Dwyer, President of the Global Alzheimer’s Platform Foundation (GAP), a patient-centric organization committed to accelerating the discovery of therapies for the treatment of Alzheimer’s, issued the following statement on […]
GAP Chairman, George Vradenburg, talks about a bold approach that the National Institute of Health (NIH) can take by partnering with America’s best biotech and pharmaceutical research centers. The U.S. needs a bold initiative to achieve transformative progress in the fight against Alzheimer’s disease, cancer, cardiovascular disease, diabetes, and countless other diseases that cut lives […]